Diabetes Treatment Safety: Adverse Events and Side Effect Evidence

Evidence related to adverse events and safety

Evidence related to adverse events, serious safety outcomes, gastrointestinal events, urinary tract infections, DKA, hyperglycemia, and treatment tolerability in diabetes studies.

Build your Evidence Workspace

Save evidence about the topics you care about.

Studies

Evidence Pairs

Strong Research Support

Relationship Confidence: 74/100

Evidence Intelligence™

Evidence Summary

A structured summary of where the evidence is strongest, mixed, or still emerging.

Executive Summary

Adverse Events and Safety evidence appears to center on Semaglutide.

Among 18 indexed studies and 7 interventions, the strongest signals are summarized from the available evidence. Semaglutide appears to be one of the clearer current evidence signals.

Evidence is consistently positive across multiple studies.
Some evidence is positive, but results are not consistent across all studies.
Early findings are encouraging, but stronger trials are needed.

Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Key Finding

Evidence is consistently positive across multiple studies.

Interventions with strongest consistent evidence

Strongest consistent evidence

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

Semaglutide appears to have a consistent beneficial signal in the indexed evidence.

View supporting studies

Evidence basis: 9 evidence pairs - 13 studies

Why this appears here

Strong evidenceConsistent resultsPositive effect signalMultiple RCTsGenerally consistentModerate evidence

Semaglutide

7 studies

EvidenceScore™

79/100

ConsistencyScore™

71/100

Metformin

4 studies

EvidenceScore™

79/100

ConsistencyScore™

80/100

Evidence Snapshot

Studies

Interventions

Outcomes

Strong evidence signals

Mixed evidence areas

Key Findings

Key patterns and insights identified across the research landscape

Evidence signal

Metformin shows evidence for Total daily insulin dose

Metformin → Total daily insulin dose

Across 3 studies, Metformin shows a evidence signal for Total daily insulin dose.

3 studies

EvidenceScore™: 79/100

View supporting studies

Evidence signal

Semaglutide shows evidence for Adverse events incidence

Semaglutide → Adverse events incidence

Across 4 studies, Semaglutide shows a consistent evidence signal for Adverse events incidence.

4 studies

EvidenceScore™: 78.71153846153847/100

View supporting studies

Moderate positive signal

Insulin therapy may improve Total daily insulin dose

Insulin therapy → Total daily insulin dose

Across 2 studies, Insulin therapy shows a consistent moderate positive signal for Total daily insulin dose.

2 studies

EvidenceScore™: 69/100

View supporting studies

Neutral signal

Dapagliflozin shows limited or neutral effect on Adverse events incidence

Dapagliflozin → Adverse events incidence

Across 1 study, Dapagliflozin shows a neutral signal for Adverse events incidence.

1 studies

EvidenceScore™: 59/100

View supporting studies

Neutral signal

Empagliflozin shows limited or neutral effect on Adverse events incidence

Empagliflozin → Adverse events incidence

Across 1 study, Empagliflozin shows a neutral signal for Adverse events incidence.

1 studies

EvidenceScore™: 59/100

View supporting studies

Supporting Evidence

Mixed or conflicting evidence

Some evidence is positive, but results are not consistent across all studies.

Areas where results are mixed

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

Semaglutide is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Top entities

Semaglutide

Metformin

Semaglutide

7 studies

EvidenceScore™

79/100

ConsistencyScore™

71/100

Why this appears here

Mixed Or Conflicting ResultsPositive Signal PresentNeutral Results Present

Evidence basis: 11 evidence pairs - 15 studies

View supporting studies

Promising but understudied

Early findings are encouraging, but stronger trials are needed.

Promising areas needing more evidence

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Metformin may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Top entities

Metformin

Insulin therapy

Metformin

4 studies

EvidenceScore™

79/100

ConsistencyScore™

80/100

Why this appears here

Positive effect signalLimited study volume

Evidence basis: 5 evidence pairs - 6 studies

View supporting studies

Question Highlights

Quick answers to the most important questions supported by the available evidence.

Explore all evidence questions

Does Semaglutide reduce adverse events incidence?

Semaglutide may improve Adverse events incidence.

Strong evidence is based on 4 supporting studies.

Population details are unavailable.

View full answer

Does Metformin improve total daily insulin dose?

Metformin may improve Total daily insulin dose.

Strong evidence is based on 3 supporting studies.

Population details are unavailable.

View full answer

Does Insulin therapy improve total daily insulin dose?

Insulin therapy may improve Total daily insulin dose.

Moderate evidence is based on 2 supporting studies.

Only a small number of supporting studies are available.

View full answer

Explore all evidence questions

Explore the Evidence

The sections below provide the complete evidence questions, supporting relationships, and underlying studies behind the summary above.

Questions Answered by the Evidence

Does Semaglutide reduce adverse events incidence?

intervention effectiveness

Strong Evidence

Semaglutide may improve Adverse events incidence.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Semaglutide
EvidenceScore™ Strong | EvidenceScore™ 78.7 | weak positive | ConsistencyScore™ Consistent | 4 studies

Why this answer: This answer is based on 4 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

Does Metformin improve total daily insulin dose?

intervention effectiveness

Strong Evidence

Metformin may improve Total daily insulin dose.

ConsistencyScore™: Results are generally consistent across studies.

Ranked evidence signals

1
Metformin
EvidenceScore™ Strong | EvidenceScore™ 79.0 | weak positive | ConsistencyScore™ Generally Consistent | 3 studies

Why this answer: This answer is based on 3 supporting studies with generally consistent results and a positive effect signal.

Limitations

Population details are unavailable.

Does Insulin therapy improve total daily insulin dose?

intervention effectiveness

Moderate Evidence

Insulin therapy may improve Total daily insulin dose.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Insulin therapy
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Consistent | 2 studies

Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.

Limitations

Only a small number of supporting studies are available.
Population details are unavailable.

Does Metformin reduce adverse events incidence?

intervention effectiveness

Emerging Evidence

Current evidence does not show a clear benefit of Metformin for Adverse events incidence.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Metformin
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

Does Insulin therapy reduce adverse events incidence?

intervention effectiveness

Emerging Evidence

Current evidence does not show a clear benefit of Insulin therapy for Adverse events incidence.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Insulin therapy
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

Does Metformin reduce gastrointestinal disorders incidence?

intervention effectiveness

Emerging Evidence

Current evidence does not show a clear benefit of Metformin for Gastrointestinal disorders incidence.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Metformin
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

Does Dapagliflozin reduce adverse events incidence?

intervention effectiveness

Emerging Evidence

Current evidence does not show a clear benefit of Dapagliflozin for Adverse events incidence.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Dapagliflozin
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

Does Empagliflozin reduce adverse events incidence?

intervention effectiveness

Emerging Evidence

Current evidence does not show a clear benefit of Empagliflozin for Adverse events incidence.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Empagliflozin
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

Evidence summary for AI and search

Among 18 indexed studies and 7 interventions, the strongest signals are summarized from the available evidence. Semaglutide appears to be one of the clearer current evidence signals.